Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lipoprotein Apheresis: Current Recommendations for Treating Familial Hypercholesterolemia and Elevated Lipoprotein(a)
Maya Safarova, Patrick M. Moriarty
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 7, pp. 391-404
Closed Access | Times Cited: 23

Showing 23 citing articles:

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Marlys L. Koschinsky, Archna Bajaj, Michael B. Boffa, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 3, pp. e308-e319
Closed Access | Times Cited: 74
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Bożena Sosnowska, Janina Stępińska, Przemysław Mitkowski, et al.
Archives of Medical Science (2024) Vol. 20, Iss. 1, pp. 8-27
Open Access | Times Cited: 18
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
Maya Safarova, Tia Bimal, Daniel Soffer, et al.
American Journal of Preventive Cardiology (2024) Vol. 19, pp. 100701-100701
Open Access | Times Cited: 10
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment
Anders Berg Wulff, Børge G. Nordestgaard, Anne Langsted
Current Atherosclerosis Reports (2024) Vol. 26, Iss. 4, pp. 111-118
Closed Access | Times Cited: 9
Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access | Times Cited: 1
Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia
Hayato Tada, Masa‐aki Kawashiri, Atsushi Nohara, et al.
Genes (2024) Vol. 15, Iss. 3, pp. 297-297
Open Access | Times Cited: 5
Lipids dysregulation in diseases: core concepts, targets and treatment strategies
Tikam Chand Dakal, Feng Xiao, Chandra Kanta Bhusal, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
Familial hypercholesterolemia in pregnancy
Fahad Alnouri, Frederick J. Raal
Current Opinion in Lipidology (2025)
Closed Access
Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis
Song Liu, X. Wang, Jiaqiang Hu, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy
Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1637-1637
Open Access | Times Cited: 4
Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects
Antonio Greco, Simone Finocchiaro, Marco Spagnolo, et al.
Circulation (2025) Vol. 151, Iss. 6, pp. 400-415
Closed Access
High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review
Qiaofei Chen, Ayiguli Abudukeremu, Kaiwen Li, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7856-7856
Open Access | Times Cited: 3
Functionalized Periodic Mesoporous Silica Nanoparticles for Inhibiting the Progression of Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol
Hao Jin, Wenbin Lu, Yahao Zhang, et al.
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 74-74
Open Access | Times Cited: 2
Recent progress in gene therapy for familial hypercholesterolemia treatment
Yaxin Luo, Yaofeng Hou, Wenwen Zhao, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110641-110641
Open Access | Times Cited: 2
Lipoprotein(a) and the atherosclerotic burden – should we wait for clinical trial evidence before taking action?
Isabella Fichtner, Chiara Macchi, Alessandra Stefania Rizzuto, et al.
Atherosclerosis Plus (2024) Vol. 58, pp. 16-23
Open Access | Times Cited: 2
Measuring lipoprotein(a) for cardiovascular disease prevention – in whom and when?
P. E. Thomas, Signe Vedel‐Krogh, Børge G. Nordestgaard
Current Opinion in Cardiology (2023) Vol. 39, Iss. 1, pp. 39-48
Closed Access | Times Cited: 5
Elevated Lp(a): Guidance for Identifying and Managing Patients
Daniel E. Hilleman, James L. Vacek, James M. Backes
Southern Medical Journal (2024) Vol. 117, Iss. 4, pp. 208-213
Closed Access | Times Cited: 1
Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to PCSK9 inhibitors: a case report and literature review
Mingjing Guan, Hao Wang, Fang Wang, et al.
Thrombosis Journal (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Administration of insulin like growth factor I (IGF I) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease
Zvi Laron, Haim Werner
Growth Hormone & IGF Research (2023) Vol. 71, pp. 101548-101548
Closed Access | Times Cited: 2
Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia
Joanna Marlęga-Linert, Katarzyna Wartecka-Zielińska, Dariusz Wydra, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 2
The 10 essential questions regarding lipoprotein(a)
Karam Kostner, Gerhard M. Kostner
Current Opinion in Clinical Nutrition & Metabolic Care (2023) Vol. 27, Iss. 2, pp. 136-143
Closed Access | Times Cited: 2
Effective exosomes reduction in hypercholesterinemic patients suffering from cardiovascular diseases by lipoprotein apheresis: Exosomes apheresis
Sophie Schröder, Robert Epple, André Fischer, et al.
Therapeutic Apheresis and Dialysis (2024)
Closed Access
Lipoprotein Apheresis: An Established Therapeutic Modality for Homozygous Familial Hypercholesterolemia Patients Refractory to PCSK9 Inhibitors: A Case Report and Literature Review
Mingjing Guan, Haolin Wang, Fang Wang, et al.
Research Square (Research Square) (2024)
Open Access
Page 1

Scroll to top